Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance

Bolormaa Vandanmagsar, Yun‐Hee Youm, Anthony Ravussin et al. · Nature Medicine · 2011 · 2.6K citations · Full text

Life Sciences, Cell Biology, Immunology +14

Interleukin-1–Receptor Antagonist in Type 2 Diabetes Mellitus

Claus M. Larsen, Mirjam Faulenbach, Allan Vaag et al. · New England Journal of Medicine · 2007 · 1.8K citations · Full text

Medicine, Endocrinology, Pharmacology +17

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.

Luciano Rossetti, Douglas J. Smith, Gerald I. Shulman et al. · Journal of Clinical Investigation · 1987 · 808 citations · Full text

Medicine, Endocrinology, Pharmacology +16

Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 Diabetes

Hyemi Lee, Jwa-Jin Kim, Hyun Jin Kim et al. · Diabetes · 2012 · 738 citations · Full text

Life Sciences, Immunology, Molecular Biology +17